INS and metabolic dysfunction-associated steatotic liver disease: In the absence of approved treatments of NAFLD, multiple pharmaceuticals are in different phases of clinical trials targeting mainly bile acid homeostasis, insulin sensitivity improvement, inflammation and lipid metabolism (2).